Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates
Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates


Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported

Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference
Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company
pioneering a new way to treat the underlying cause of severe genetic
diseases by precisely upregulating protein

Stoke Therapeutics Added to NASDAQ Biotechnology Index
Stoke Therapeutics Added to NASDAQ Biotechnology Index


Stoke Therapeutics, Inc. (Nasdaq:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference
Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting
Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update


Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported

Stoke Therapeutics to Present at Upcoming Investor Conferences in November
Stoke Therapeutics to Present at Upcoming Investor Conferences in November


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

Health Canada bestätigt RavenQuest´s Technologie
Health Canada bestätigt RavenQuest´s Technologie
​Das innovative kanadische Cannabisunternehmen RavenQuest BioMed Inc. (ISIN: CA7543871080 / CSE: RQB), informiert seine Aktionäre angesichts der jüngst erreichten signifikanten Meilensteine über
RavenQuest BioMed – steigende Profitabilität bei sich beschleunigendem Wachstum
RavenQuest BioMed – steigende Profitabilität bei sich beschleunigendem Wachstum
​Auf seiner aktuellen Roadshow berichtete der kanadische Kannabisproduzent RavenQuest BioMed Inc. (ISIN: CA7543871080 / CSE: RQB) ausführlich über die aktuelle Situation im Unternehmen. Demzufolge
RavenQuest BioMed expandiert nach Europa
RavenQuest BioMed expandiert nach Europa
​Wie der stark wachsende kanadische Cannabishersteller RavenQuest BioMed Inc. (ISIN: CA7543871080 / CSE: RQB) mitteilte, hat man ein Abkommen über ein 50/50 Joint Venture mit der norwegischen Cannabis
Cannabisproduktion steigt um 275 %
Cannabisproduktion steigt um 275 %
​Spitzen Nachrichten vom lizenzierten und staatlich anerkannten Cannabishersteller RavenQuest BioMed Inc. (ISIN: CA7543871080 / CSE: RQB). Wie das Unternehmen mitteilte, hat man die letzte Genehmigung
RavenQuest bezieht hochwertige Cannabisstämme von alteingesessenem Profi
RavenQuest bezieht hochwertige Cannabisstämme von alteingesessenem Profi
​In seiner jüngsten Unternehmensmeldung gab das kanadische Cannabisunternehmen RavenQuest BioMed (ISIN: CA7543871080 / CSE: RQB) bekannt, dass man ein Abkommen (‚Letter of Intent‘) unterzeichnet habe,
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal®

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on November 15, 2023 and

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided

Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28

Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock options

Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive

Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023.

Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives


Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company’s staff. By consolidating

Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing


Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic

Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the launch of the Early Access Program for NeXT Personal Dx, a tumor-informed, whole